Freedom Broker initiated coverage of iRadimed with a Buy rating and $116 price target. The profitable, dividend-paying iRadimed "appears to be the only company" that offers both a nonmagnetic MRI-compatible IV infusion pump and a non-magnetic MRIcompatible patient monitoring system, says the analyst, who cites multiple product-driven upgrade cycles, the rapid scaling of the ferromagnetic detection product, and an underappreciated international expansion opportunity for the firm's bullish stance.
